MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis

I Tchetverikov, H K Ronday, B van El, G H Kiers, N Verzijl, J M TeKoppele, T W J Huizinga, J DeGroot, R Hanemaaijer

Objective: To analyse matrix metalloproteinases (MMPs) and tissue inhibitor-1 of MMPs (TIMP-1) levels in the systemic circulation and synovial fluid (SF) of patients with RA and to compare these levels with inflammatory and collagen degradation markers.

Methods: ProMMP-1, -2, -3, -8, -9, TIMP-1, levels of MMP/α2-macroglobulin complexes, and collagen degradation products were measured by sandwich ELISA, activity assays, and HPLC in paired SF and serum samples from 15 patients with RA and 13 with OA.

Results: MMPs were higher in SF of patients with RA than in OA or controls. MMP levels in SF of patients with OA were higher than in controls. In serum, levels of proMMP-3, -8 and -9 were higher in patients with RA than in OA or controls, whereas only proMMP-8 and -9 were higher in serum of patients with OA than in controls. A strong correlation was seen between serum and SF levels of MMP-8 and -9 in RA. Increased levels of MMP/α2-macroglobulin complexes indicated an MMP/TIMP imbalance in serum and SF in RA. SF hydroxyproline correlated significantly with SF levels of proMMP-3 and TIMP-1 in RA.

Conclusions: Systemic MMP-8 and -9 levels represent the situation in the inflamed joint; MMP-9 is likely to be involved in degradation of joint collagen. The hypothesis of MMP/TIMP imbalance in RA is strengthened.

The above mentioned studies show that significant progress has been made on identification of MMPs involved in the disease process in RA. However, studies on multiple MMP subclasses and/or the relationship between local and systemic levels of the different MMP subclasses are scarce. This study was designed to provide a broad analysis of the MMPs which play a part in RA pathology and to investigate the relation between local and systemic levels of MMPs and their tissue inhibitor (TIMP). Furthermore, the relation between the studied MMPs and systemic marker of inflammation, CRP, and joint collagen degradation products, hydroxyproline (OHPro), in patients with RA was investigated.

MATERIALS AND METHODS

Hydroxyproline measurements

OHPro was measured in diluted SF samples by high performance liquid chromatography after acid hydrolysis, according to the method described by Bank et al.7

ProMMPs and TIMP-1

ProMMP-3 and -13 and TIMP-1 were measured using the sandwich enzyme linked immunosorbent assay (ELISA; Amersham Biosciences, Little Chalfont, UK). ProMMP-1, -2, -8, and -9 were detected using specific MMP activity assays (Biotrak activity assay, Amersham Biosciences, Little Chalfont, UK).

MMP activity in MMP/α2-macroglobulin complexes

MMP activity in α2-macroglobulin (α2M) complexes was determined using small fluorogenic substrates, according to the modified method described by Beekman et al.8 Riley et al.9 and DeGroot et al.10

Paired serum/SF samples

Paired SF and serum samples from 15 patients with RA and 13 with OA were collected during therapeutic arthrocentesis of a knee joint. Nine SF samples of traffic casualties, obtained at post mortem, were used as controls (material was obtained with the informed consent of relatives); 15 healthy volunteers provided control serum samples. Table 1 shows the basic characteristics of the patient groups.

Statistical analysis

The Kruskal-Wallis test was used to assess differences between study groups, which were further analysed using the Mann-Whitney U test. Correlations were evaluated using Pearson’s correlation or Spearman rank correlation coefficients with SPSS software (Chicago, IL, USA). A value of p<0.05 was considered significant.

Abbreviations: α2M, α2-macroglobulin; CRP, C reactive protein; MMPs, matrix metalloproteinases; OHPro, hydroxyproline; RA, rheumatoid arthritis; SF, synovial fluid; TIMP, tissue inhibitors of metalloproteinases.
RESULTS

Table 2 shows the median values of the SF and serum levels of the studied MMPs and TIMP-1. As expected, highly increased levels of MMPs were found in the SF of patients with RA as compared with the control group. Also, OA SF MMP levels were significantly higher than in the control group, although they were lower than in RA. In contrast with SF, only proMMP-3, -8, and -9 levels were increased in the serum of patients with RA when compared with the control group or patients with OA. ProMMP-13 levels were below the detection limit in both compartments in all groups.

Significant correlations were found between SF and serum proMMP-9 ($r_s = 0.718$, $p < 0.003$) and proMMP-8 ($r_s = 0.664$, $p < 0.007$) levels in patients with RA. Further, levels of the studied MMPs were higher in SF than in the systemic circulation ($p < 0.001$) in the RA group, except for proMMP-9 levels ($p = 0.78$).

To assess the degree of the continuing joint tissue degradation during acute joint effusion, OHPro levels in SF were analysed. No significant difference was found between the OHPro levels in RA and OA SF (median (25th–75th centiles): 14.4 (10.8–17.2) vs 11.8 (9.3–19.8), $p = 0.68$). A significant correlation was found between SF proMMP-9 levels and OHPro in the RA group (table 3). Also, a trend towards a correlation was seen between SF proMMP-8 and OHPro, whereas no correlation was found between OHPro and SF proMMP-3 or systemic CRP levels.

In SF, the following distribution pattern of the proMMPs was seen: RA > OA > controls. However, TIMP-1 showed a different distribution pattern: RA = OA > controls, which implies an imbalance within the proteolytic system in favour of the MMPs. Moreover, higher levels of MMP in complex with $\alpha_2$M (activated, but not-TIMP inhibited MMPs are likely to form complexes with $\alpha_2$M$^3$) were found in patients with RA than in control or OA groups, strengthening the hypothesis of an MMP/TIMP imbalance.

DISCUSSION

This study provides an extensive analysis of MMPs, TIMP-1, and the MMP/$\alpha_2$M complex in paired serum and SF samples of patients with RA and OA and controls with healthy knees. The highest MMP levels in the SF of patients with RA were found for proMMP-1, -3, -8, and -9. Whereas MMP-3 and -9 were also detectable in control SF, MMP-1 and -8 were found in control SF only at extremely low concentrations. MMP levels in the SF of patients with OA were lower than in RA, but significantly higher than in control SF, indicating that use of OA material as a control for patients with RA may not always be appropriate. Interestingly, MMP-8 and MMP-9 levels correlated with each other in the SF of both RA and OA groups. Also, MMP-1 and MMP-3 levels correlated with each other in RA and OA groups, probably indicating the predominant cell source of these MMPs: macrophages and neutrophils for MMP-8 and -9 and synovial cells for MMP-1 and -3. MMP analysis in the systemic circulation of patients with RA and OA indicated that not all MMP locally involved (as shown by the increased SF levels) are also increased in serum. High serum levels of MMP-3, -8, and -9 were found in RA, whereas only MMP-8 and -9 were also found to be increased in the serum of patients with OA.

Furthermore, strong correlations between serum and SF levels of proMMP-8 and -9, which were both increased in the SF and serum of patients with RA were found, suggesting

<table>
<thead>
<tr>
<th>Table 1 Characteristics of the patients groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristic</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Male/female</td>
</tr>
<tr>
<td>Disease duration (years)</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
</tr>
<tr>
<td>RF positive</td>
</tr>
</tbody>
</table>

Results are shown as mean (SD).

CRP, C reactive protein; RF, rheumatoid factor.

<table>
<thead>
<tr>
<th>Table 2 Median (25th–75th centiles) values of serum and SF MMP levels</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synovial fluid</strong></td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>MMP-1 (U/ml)</td>
</tr>
<tr>
<td>0.00 (0.0–0.01)</td>
</tr>
<tr>
<td>MMP-8 (U/ml)</td>
</tr>
<tr>
<td>MMP-3 (mg/ml)</td>
</tr>
<tr>
<td>MMP-2 (U/ml)</td>
</tr>
<tr>
<td>MMP-9 (U/ml)</td>
</tr>
<tr>
<td>MMP-13</td>
</tr>
<tr>
<td>MMP/$\alpha_2$M (U/ml)</td>
</tr>
<tr>
<td>TIMP-1 (ng/ml)</td>
</tr>
</tbody>
</table>

**Serum**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>MMP-1 (U/ml)</td>
<td>Controls</td>
<td>OA</td>
</tr>
<tr>
<td>0.06 (0.02–0.01)</td>
<td>0.06 (0–0.1)</td>
<td>0.06 (0.06–0.1)</td>
</tr>
<tr>
<td>MMP-8 (U/ml)</td>
<td>0.64 (0–6.1)</td>
<td>1.12 (0.7–2.6)†</td>
</tr>
<tr>
<td>MMP-3 (mg/ml)</td>
<td>16 (11–25)</td>
<td>17 (12–28)</td>
</tr>
<tr>
<td>MMP-2 (U/ml)</td>
<td>56 (4.7–6.4)</td>
<td>6 (4.9–7.0)</td>
</tr>
<tr>
<td>MMP-9 (U/ml)</td>
<td>2.1 (1.6–2.6)</td>
<td>3.0 (2.0–3.6)*</td>
</tr>
<tr>
<td>MMP-13</td>
<td>Not detectable</td>
<td>Not detectable</td>
</tr>
<tr>
<td>MMP/$\alpha_2$M (U/ml)</td>
<td>86 (77–128)</td>
<td>88 (80–145)</td>
</tr>
<tr>
<td>TIMP-1 (mg/ml)</td>
<td>445 (428–627)</td>
<td>495 (412–1368)</td>
</tr>
</tbody>
</table>

*p < 0.001 RA vs OA; **p < 0.05 RA vs OA; *p < 0.001 RA vs OA controls; †p < 0.05 RA vs controls; ‡p < 0.001 OA vs controls; ††p < 0.05 OA vs controls.

MMP, TIMP, and MMP activity in MMP/$\alpha_2$M levels in serum and synovial fluid of patients with RA and OA. Values shown are median (25th–75th centiles).
that serum levels of these enzymes may be used to assess the situation in inflamed joints.

To elucidate the involvement of different MMP subclasses in joint inflammation and tissue degradation, MMP levels were compared with markers of systemic inflammation (CRP) and the collagen degradation marker, OHPro. Only proMMP-3 levels in SF correlated with CRP levels, which is consistent with findings by others. SF OHPro levels did not correlate with proMMP-3, whereas a significant correlation with proMMP-9 levels and a trend towards correlation with proMMP-8 were found. These results are in line with in vitro data on collagen degradation: collagen, one of the main components of the articular cartilage, can be specifically cleaved by collagenases into the characteristic 1/4 and 1/2 fragments, which can be further degraded by gelatinases. Thus, the results provide in vivo indication of MMP-9 involvement in collagen degradation in the joints of patients with RA. Taken together, these results show that MMP-8 and -9 are likely to play a part in the degradation of the collagenous network of joint tissue, whereas proMMP-3 levels are likely to reflect the inflammatory component of the disease process.

An ample body of evidence suggests the presence of an AMP/TIMP imbalance in arthritic diseases. Based on molar ratios, TIMPs levels seem to be insufficient to counteract increased MMP production levels in RA. Our results of equally increased TIMP-1 levels in the serum and SF of patients with OA and RA and higher levels of proMMPs in RA are in line with this hypothesis. Furthermore, in the SF and serum of patients with RA high levels of active MMPs in complex with TIMP-2 and TIMP-4 are present, also indicating an AMP/TIMP imbalance in RA as compared with the normal situation or patients with OA. The importance of the MMP/TIMP imbalance in RA is also indicated by higher AMP activity levels at the inflammation site (SF) as compared with the serum levels, because no difference was seen between local and systemic levels in OA.

In conclusion, this study provides an extensive analysis of systemic and SF levels of major MMP subclasses in patients with RA and OA. Furthermore, the results (a) show that systemic levels of MMP-8 and -9 are representative for the levels of these enzymes in the inflamed joints; (b) may indicate involvement of MMP-9 in generation of collagen degradation products in the SF of patients with RA; and (c) are in accordance with the hypothesis of an AMP/TIMP imbalance in RA.

**Authors’ affiliations**

T Chetverikov, T W J Huizinga, Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands

H K Ronday, Department of Rheumatology, Rheyuengen Hospital, The Hague, The Netherlands

Correspondence to: Dr R Hanemaaijer, TNO Prevention and Health, PO Box 2215, 2301 CE, Leiden, The Netherlands; R.Hanemaaijer@pg.tno.nl

Accepted 17 August 2003

**REFERENCES**


MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis

I Tchetverikov, H K Ronday, B van El, G H Kiers, N Verzijl, J M TeKoppele, T W J Huizinga, J DeGroot and R Hanemaaijer

doi: 10.1136/ard.2003.013243

Updated information and services can be found at:
http://ard.bmj.com/content/63/7/881

These include:

References

This article cites 13 articles, 3 of which you can access for free at:
http://ard.bmj.com/content/63/7/881#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Connective tissue disease (4253)
Degenerative joint disease (4641)
Immunology (including allergy) (5144)
Musculoskeletal syndromes (4951)
Rheumatoid arthritis (3258)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/